Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,978 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antiviral Compounds Screening Targeting HBx Protein of the Hepatitis B Virus.
Ma Y, Nakamoto S, Ao J, Qiang N, Kogure T, Ogawa K, Nakagawa M, Fujiwara K, Iwanaga T, Kojima R, Kanzaki H, Koroki K, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Nakagawa R, Ogasawara S, Muroyama R, Chiba T, Kato J, Kato N. Ma Y, et al. Among authors: nakagawa m, nakagawa r. Int J Mol Sci. 2022 Oct 10;23(19):12015. doi: 10.3390/ijms231912015. Int J Mol Sci. 2022. PMID: 36233317 Free PMC article.
Exploring microsatellite instability in patients with advanced hepatocellular carcinoma and its tumor microenvironment.
Mukai S, Kanzaki H, Ogasawara S, Ishino T, Ogawa K, Nakagawa M, Fujiwara K, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Koroki K, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Saito T, Nakagawa R, Suzuki E, Ooka Y, Muroyama R, Nakamoto S, Tawada A, Chiba T, Arai M, Kato J, Shiina M, Ota M, Ikeda JI, Takiguchi Y, Ohtsuka M, Kato N. Mukai S, et al. Among authors: nakagawa m, nakagawa r. JGH Open. 2021 Oct 1;5(11):1266-1274. doi: 10.1002/jgh3.12660. eCollection 2021 Nov. JGH Open. 2021. PMID: 34816012 Free PMC article.
Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial.
Ogasawara S, Koroki K, Makishima H, Wakatsuki M, Takahashi A, Yumita S, Nakagawa M, Ishino T, Ogawa K, Fujiwara K, Iwanaga T, Sakuma T, Fujita N, Kojima R, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Ozawa Y, Kawasaki Y, Kurokawa T, Hanaoka H, Tsuji H, Kato N. Ogasawara S, et al. Among authors: nakagawa m, nakagawa r. BMJ Open. 2022 Apr 8;12(4):e059779. doi: 10.1136/bmjopen-2021-059779. BMJ Open. 2022. PMID: 35396315 Free PMC article.
Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysis.
Ozeki Y, Kanogawa N, Ogasawara S, Ogawa K, Ishino T, Nakagawa M, Fujiwara K, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Kojima R, Kanzaki H, Koroki K, Kobayashi K, Nakamura M, Kiyono S, Kondo T, Saito T, Nakagawa R, Suzuki E, Ooka Y, Nakamoto S, Muroyama R, Tawada A, Chiba T, Arai M, Kato J, Ikeda JI, Takiguchi Y, Kato N. Ozeki Y, et al. Among authors: nakagawa m, nakagawa r. Int J Clin Oncol. 2022 Sep;27(9):1459-1466. doi: 10.1007/s10147-022-02195-9. Epub 2022 Jun 15. Int J Clin Oncol. 2022. PMID: 35704154
Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience.
Ogawa K, Kanzaki H, Chiba T, Ao J, Qiang N, Ma Y, Zhang J, Yumita S, Ishino T, Unozawa H, Kan M, Iwanaga T, Nakagawa M, Fujiwara K, Fujita N, Sakuma T, Koroki K, Kusakabe Y, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Saito T, Nakagawa R, Ogasawara S, Suzuki E, Nakamoto S, Muroyama R, Kanda T, Maruyama H, Mimura N, Kato J, Motohashi S, Kato N. Ogawa K, et al. Among authors: nakagawa m, nakagawa r. J Cancer. 2022 May 16;13(8):2656-2661. doi: 10.7150/jca.71494. eCollection 2022. J Cancer. 2022. PMID: 35711837 Free PMC article.
Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
Nakagawa M, Inoue M, Ogasawara S, Maruta S, Okubo T, Itokawa N, Iino Y, Obu M, Haga Y, Seki A, Kikuchi Y, Kogure T, Yumita S, Ishino T, Ogawa K, Fujiwara K, Iwanaga T, Fujita N, Sakuma T, Kojima R, Kanzaki H, Koroki K, Taida T, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Itobayashi E, Atsukawa M, Koma Y, Azemoto R, Ito K, Mizumoto H, Shinozaki M, Kato J, Kato N. Nakagawa M, et al. Among authors: nakagawa r. Cancer. 2023 Feb 15;129(4):590-599. doi: 10.1002/cncr.34559. Epub 2022 Nov 24. Cancer. 2023. PMID: 36426410 Free article.
The efficacy of contrast-enhanced computed tomography on the management of gastroesophageal varices in patients with hepatocellular carcinoma.
Kondo T, Fujiwara K, Nakagawa M, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Ogasawara S, Suzuki E, Ooka Y, Nakamoto S, Chiba T, Arai M, Kato J, Kato N. Kondo T, et al. Among authors: nakagawa m. Sci Rep. 2022 Dec 1;12(1):20726. doi: 10.1038/s41598-022-25350-8. Sci Rep. 2022. PMID: 36456830 Free PMC article.
Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cells.
Iwanaga T, Chiba T, Nakamura M, Kaneko T, Ao J, Qiang N, Ma Y, Zhang J, Kogure T, Yumita S, Ishino T, Ogawa K, Kan M, Nakagawa M, Fujiwara K, Fujita N, Sakuma T, Kanzaki H, Koroki K, Kusakabe Y, Inoue M, Kobayashi K, Kanogawa N, Kiyono S, Kondo T, Nakagawa R, Ogasawara S, Nakamoto S, Muroyama R, Kato J, Kanda T, Maruyama H, Mimura N, Honda T, Murayama T, Nakamura H, Kato N. Iwanaga T, et al. Among authors: nakagawa m, nakagawa r. Biochem Biophys Res Commun. 2023 Jan 29;642:192-200. doi: 10.1016/j.bbrc.2022.12.025. Epub 2022 Dec 10. Biochem Biophys Res Commun. 2023. PMID: 36586187
Successful Identification of a Novel Therapeutic Compound for Hepatocellular Carcinoma Through Screening of ADAM9 Inhibitors.
Ogawa K, Chiba T, Nakamura M, Arai J, Zhang J, Ma Y, Qiang NA, Ao J, Yumita S, Ishino T, Kan M, Iwanaga T, Nakagawa M, Fujiwara K, Sakuma T, Kanzaki H, Koroki K, Kusakabe Y, Kobayashi K, Kanogawa N, Kiyono S, Kondo T, Nakagawa R, Ogasawara S, Muroyama R, Nakamoto S, Kanda T, Maruyama H, Kato J, Matsumoto S, Arai T, Motohashi S, Kato N. Ogawa K, et al. Among authors: nakagawa m, nakagawa r. Anticancer Res. 2023 Mar;43(3):1043-1052. doi: 10.21873/anticanres.16249. Anticancer Res. 2023. PMID: 36854524
Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma.
Kanogawa N, Ogasawara S, Maruta S, Iino Y, Obu M, Ishino T, Ogawa K, Yumita S, Iwanaga T, Unozawa H, Nakagawa M, Fujiwara K, Sakuma T, Fujita N, Kojima R, Kanzaki H, Koroki K, Kobayashi K, Inoue M, Kiyono S, Nakamura M, Kondo T, Saito T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Itobayashi E, Koma Y, Azemoto R, Kato J, Kato N. Kanogawa N, et al. Among authors: nakagawa m, nakagawa r. BMC Gastroenterol. 2023 Mar 11;23(1):70. doi: 10.1186/s12876-023-02674-x. BMC Gastroenterol. 2023. PMID: 36906542 Free PMC article.
3,978 results